Mycophenolate Mofetil Therapy for Sarcoidosis-Associated Uveitis

@article{Bhat2009MycophenolateMT,
  title={Mycophenolate Mofetil Therapy for Sarcoidosis-Associated Uveitis},
  author={Pooja V. Bhat and Rene Antonio Cervantes-Casta{\~n}eda and Priyanka P Doctor and Fahd Anzaar and Christopher S Foster},
  journal={Ocular Immunology and Inflammation},
  year={2009},
  volume={17},
  pages={185 - 190}
}
Purpose: To evaluate the control of ocular inflammation and the steroid sparing effect in patients with sarcoidosis-associated uveitis treated with mycophenolate mofetil (MMF). Methods: Retrospective case series. All patients with a diagnosis of sarcoidosis-associated uveitis that were treated with MMF between 2005 and 2007 were identified. The dose and duration of MMF therapy and side effects were recorded. Results: Seven patients (14 eyes) with sarcoidosis-associated uveitis were treated with… Expand
Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy
TLDR
It is suggested that MMF is effective in CNS sarcoidosis but not in Sarcoid myopathy, with a corticosteroid sparing effect and a better tolerance profile than other immunosuppressive agents. Expand
Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis
TLDR
The data show that mycophenolate mofetil is generally effective and well tolerated in the treatment of chronic non-infectious uveitis. Expand
Effect and Safety of Mycophenolate Mofetil in Chronic Pulmonary Sarcoidosis: A Retrospective Study
TLDR
This study indicates that the addition of MMF to corticosteroids is a viable and safe treatment option in CPS, and allows a significant reduction of maintenance cortICosteroids to levels <10 mg/day while preserving a stable or improved clinical condition. Expand
Uveitis profile and treatment response in Iranian patients with sarcoidosis
TLDR
Use of immunomodulatory drugs combined with corticosteroids resulted in good visual outcome and control of uveitis with a possible fewer Corticosteroid side effects. Expand
Mycophenolate Mofetil in the Treatment of Chronic Non-infectious, Non-necrotizing Scleritis
TLDR
MMF is an effective and well-tolerated therapy that can successfully reduce inflammation and decrease CS use in the treatment of chronic non-infectious, non-necrotizing scleritis. Expand
Enteric-coated Mycophenolate Sodium as a Corticosteroid-sparing Agent for the Treatment of Autoimmune Scleritis
TLDR
Enteric-coated mycophenolate sodium (EC-MPS) can be used as a corticosteroid-sparing agent to safely suppress inflammatory autoimmune scleritis. Expand
Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis
TLDR
An uncommon case of a 34-year-old male of sarcoid uveitis who developed extensive herpes zoster while on treatment with Mycophenolate mofetil is reported. Expand
[Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. TheExpand
Ocular Sarcoidosis.
TLDR
Only very rarely does sarcoid uveitis fail to respond to combined corticosteroids and methotrexate therapy, a situation that should suggest either poor adherence or another granulomatous disease. Expand
Sarcoidosis and uveitis.
TLDR
Diagnostic criteria for sarcoidosis uveitis when biopsy is unavailable or negative are established based on a combination of ophthalmological findings and laboratory tests, and infliximab and adalimumab have been recently proposed for the treatment of refractory or sight-threatening systemic sarcoIDosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.
TLDR
Mycophenolate mofetil is a safe and effective steroid-sparing immunomodulatory agent and can be considered an important addition to the authors' armamentarium in the care of patients with ocular inflammatory disease. Expand
Mycophenolate mofetil therapy for inflammatory eye disease.
TLDR
Data suggest that mycophenolate mofetil may be an effective corticosteroid-sparing agent in the treatment of inflammatory eye disease with a manageable side effect profile. Expand
Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
TLDR
It is suggested that mycophenolate mofetil is a useful immunosuppressive drug for controlling ocular inflammation with minimal side effects. Expand
Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis
TLDR
It is shown that MMF controls the disease in the majority of patients with an acceptable profile of side effects and was judged ineffective due to failure to reduce the number of recurrences of severe inflammation compared with the previous therapeutic regime, or indeed occurrence of persistent macular oedema. Expand
Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
TLDR
It seems that AZA still is the immunouppressant of choice in chronic active CD, but MMF is a reasonable alternative in patients who do not tolerate AZA. Expand
[Ocular sarcoidosis. Retrospective study of 18 cases].
TLDR
An adequate control of ocular inflammation may improve the prognosis in patients with ocular sarcoidosis and Posterior segment involvement (posterior uveitis, macular edema or epiretinal membrane) may be associated with a worse visual prognosis. Expand
Therapy of rheumatoid arthritis with mycophenolate mofetil.
  • R. Goldblum
  • Medicine
  • Clinical and experimental rheumatology
  • 1993
TLDR
Treatment with mycophenolate mofetil reduces rheumatoid factor titres, immunoglobulin levels, and the total number of T cells in RA patient peripheral blood; in addition, lymphocyte mitogen responses are inhibited and delayed hypersensitivity skin test reactivity is decreased. Expand
Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil
TLDR
The report of a child with severe renal failure secondary to renal limited sarcoidosis who was successfully treated with corticosteroid induction therapy and has been in sustained remission for over a year with mycophenolate mofetil monotherapy. Expand
Uveitis as a presenting feature of chronic sarcoidosis.
TLDR
Any uveitis of unknown origin may be due to sarcoidosis, although its systemic manifestations may not occur for up to 11 yrs, and Uveitis patients need a very long-term follow-up, including periodic diagnostic tests for systemic sarcoids. Expand
Mycophenolate mofetil may serve as a steroid‐sparing agent for sarcoidosis
TLDR
The first successful and safe use of MMF is reported in five patients with sarcoidosis, marking a new step in the development of immunosuppressive drugs for inflammatory diseases. Expand
...
1
2
3
...